Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial – OncoDaily
Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial / Avelumab, axitinib, cancer, ESMO Annals of Oncology, Javelin Renal 101 trial, OncoDaily,
Related Articles
An NHS Christmas Carol
By Craig Nikolic Our tale begins with a bitter and unhappy NHS senior manager, wondering about another year where nothing seems to be better, and…
Louisiana forbids public health workers from promoting COVID, flu and mpox shots
An NPR investigation found Louisiana health officials told staff to stop promoting vaccines for COVID, flu and mpox, holding flu shot events or otherwise encouraging…
Home – Wastewater talks. We listen.
Through wastewater monitoring, we track twelve infectious diseases across the country and share our findings here.
‘Obelisks’: Entirely New Class of Life Has Been Found in The Human Digestive System
Ancient relics within.
Vaccines don’t cause autism. What does?
Scientists say most brain changes that contribute to autistic traits occur before birth.
Taxi drivers are steering neuroscience toward better understanding Alzheimer’s
A new study shows taxi drivers die at lower rates from Alzheimer’s disease than people with other professions.
Deprescribing antidepressants for depression – what is the evidence for and against? – Jeffrey CL Looi, Stephen Allison, Tarun Bastiampillai, Steve Kisely, Paul A Maguire, Luke S-C Woon, Katrina Anderson, Gin S Malhi, 2024
Objective Recent guidelines suggest that the overall quantity and duration of antidepressant prescriptions should be reduced. In this paper, we comment on the e…
Deprescribing antidepressants: An integral and neglected component of high-quality prescribing practice – Mark Abie Horowitz, David Taylor, 2024
View all access and purchase options for this article. 1. Looi JC, Allison S, Bastiampillai T, et al. (2024) Deprescribing antidepressants for depression – what…
When to Stay or Leave Your Physician Job – FREE Webinar
At the free, LIVE class, you’ll get everything you need to make your decision & upgrade your job in 2025, regardless if you stay or…
